Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priscilla Latta

Undersea and Hyperbaric Medicine Albany, OR Medical Doctor

NPI 1639154974 CMS profile 1206815

400 Hickory St Nw Ste 101, Albany, OR 97321

Open in the dashboard

General payments

$425

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priscilla Latta of Albany, OR is reported in the CMS Open Payments database as having received $425 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $208 2
2024 General $88 3
2023 General $16 1
2021 General $65 1
2020 General $35 2
2019 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priscilla Latta
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Priscilla Latta were reported at $208. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Priscilla Latta Undersea and Hyperbaric Medicine median Middle half National median
2019 $13 $201 $85–$538 $163
2020 $35 $84 $31–$222 $114
2021 $65 $138 $52–$383 $132
2022 $0 $135 $51–$385 $149
2023 $16 $143 $75–$442 $160
2024 $88 $178 $80–$442 $164
2025 $208 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $238 3 payments
  2. Acera Surgical, Inc. $65 1 payment
  3. Medtronic, Inc. $42 1 payment
  4. KCI USA, Inc $35 2 payments
  5. Pfizer Inc. $16 1 payment
  6. Boston Scientific Corporation $16 1 payment
  7. Medline Industries, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $425 10 payments
Products named General payments · program years 2019–2025
  1. Kerecis SurgiClose Wound Care $208 2 payments
  2. Kerecis SurgiClose Wound Care $208 2 payments
  3. Kerecis SurgiClose Wound Care $208 2 payments
  4. Kerecis GraftGuide $208 2 payments
  5. Kerecis SurgiClose Wound Care $208 2 payments
  6. Restrata Wound Matrix $65 1 payment
  7. VENASEAL $42 1 payment
  8. SNAP $35 2 payments
  9. Kerecis Omega3 SurgiClose $30 1 payment
  10. Kerecis Omega3 Marigen $30 1 payment
  11. Other $182 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

180

Prescriptions dispensed, refills included

Drug cost

$1,900

Paid at the pharmacy, in all

Branded share of claims

19.4%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 37 $702
Doxycycline Hyclate Generic 25 $459
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $198
Ciprofloxacin Hcl Generic 26 $151
Cephalexin Generic 18 $116
Mupirocin Generic 14 $110
Prednisone Generic 12 $65
Levofloxacin Generic 13 $62
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$34,380

Medicare's payments for the services billed

Medicare patients

128

Average age 73

Services billed

573

68 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 45%
Chronic kidney disease 41%
Depression 38%
Heart failure 34%
Atrial fibrillation 34%
Ischemic heart disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record